SLSolenne Le Louet

Solenne Le Louet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Solenne Le Louet has a total of 168 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandra Salmon

    34Department of Pediatric Hematology and Oncology, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France

    3 shared publications
  • Aurore Chevallier

    French Reference Center for Langerhans Cell Histiocytosis, Assistance Publique des Hopitaux de Paris, Trousseau Hospital, Paris, France

    3 shared publications
  • Jean Donadieu

    Hopital Trousseau, Paris, France

    3 shared publications
  • Jean-François Emile

    Paris-Saclay University, Versailles SQY University, EA4340-BECCOH, Assistance Publique-Hôpitaux de Paris (AP-HP), Ambroise-Paré Hospital, Smart Imaging, Service de Pathologie, Boulogne, France

    3 shared publications
  • Ahmed Idbaih

    71Service de Neuro-Oncologie-Institut de Neurologie, Hôpitaux Universitaires La Pitié–Salpêtrière-Charles Foix, Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Institut du Cerveau–Paris Brain Institute, INSERM, Centre National de la Recherche Scientifique, Paris, France

    2 shared publications
  • Anne Lambilliotte

    Department of Pediatric Hematology, Centre Hospitalo-Universitaire (CHU) de Lille, Lille, France

    2 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients

    by Jean Donadieu, Dmitry Evseev, Francesco Pegoraro, Elena Sieni, Olga Slater, Caroline Hutter, Itziar Astigarraga, Thomas Lehrnbecher, Cor van Den Bos, Mathieu Simonin, et al.

    We evaluated long-term outcomes of 288 children with refractory-Langerhans cell histiocytosis (R-LCH) from 26 countries, who were prescribed off-label MAPK inhibitors (MAPKis) according to clinical indications. MAPKi indications included 148 R-risk-organ–positive (R-RO+), 67 R-risk-organ–negative (R-RO–), 13 lung destruction (lung), 9 sclerosing cholangitis (SC), 49 neurodegeneration (ND), and 2 diabetes insipidus (DI) cases. Median ages at diagnosis and MAPKi onset were 1.3 and 2.3 years, respectively, with median follow-up of 3.7 years (1166 person-years). Agents mostly prescribed as monotherapies were 184 prescriptions of vemurafenib, 115 of dabrafenib, 3 of encorafenib, 42 of cobimetinib, 45 of trametinib, and/or 1 prescription of binimetinib; followed 51 times by various chemotherapies or hematopoietic stem-cell transplantation, or 28 times by combined anti-BRAF–anti-MEK. Short-term responses (<8 weeks) ranged from 98% (R-RO+ and R-RO–), to 30% (lung) to none (ND, DI, and SC); although long-term lung and ND responses could be observed. Skin rash was the most frequent adverse event (∼55%), and 7 others included 1 case of cardiomyopathy and 6 of retinitis. Five developed MAPKi-unrelated tumors and 9 patients died. Five-year survival was 98%. After 113 patients with R-LCH discontinued MAPKi, 69 experienced disease reactivation. None of the various empirical maintenance therapies were able to prevent secondary reactivation. Among the 143 assessable patients without ND-LCH at MAPKi onset, 60 developed ND (45%, 5-year risk). MAPKis appeared to be safe and effective in children with R-RO+/RO–LCH, whereas other indications’ responses were less frequent or occurred later. Further studies are needed to find effective maintenance-therapy approaches, particularly to prevent frequently observed secondary ND.


  • Neurofilament as a biomarker of neurodegeneration in childhood Langerhans cell histiocytosis: A feasibility study on 273 patients

    by Solenne Le Louet, Camille Brunaud, Mohamed Barkaoui, Aurore Chevallier, François Chalard, Ludovic Mansuy, Alexandra Salmon, Nimrod Buchbinder, Saba Azarnoush, Sophie Pertuisel, et al.

    Summary: Neurodegeneration (ND) is a severe complication of Langerhans cell histiocytosis (LCH), often leading to progressive neurological decline. We evaluated the usefulness of using plasma and cerebrospinal fluid neurofilament light chain (p‐ and CSF‐NFL) levels as biomarkers to identify and monitor ND‐LCH. NFL levels were measured using the single‐molecule array for a subset of patients from the French National LCH Registry. NFL levels in 692 plasma and 115 CSF samples from 273 registry‐enrolled children were analysed. Based on 84 paired plasma and CSF samples from 67 patients, p‐ and CSF‐NFL levels were strongly correlated ( p < 0.0001). The areas under the receiver operating characteristics curves for ND‐LCH were 72% (95% confidence interval [CI], 64%–78%) for p‐NFL and 94% (95% CI, 88%–98%) for CSF‐NFL. The highest p‐NFL (13.7 vs. 7.2 pg/mL; z ‐score 2.3 vs. 0.6) and CSF‐NFL (436.9 vs. 65.2 pg/mL) levels were significantly higher for ND‐LCH than in no‐ND‐LCH patients, respectively ( p < 0.0001). Plasma NFL levels were not elevated at LCH diagnosis. At LCH diagnosis, p‐NFL was not predictive of ND, but it may serve as a minimally invasive screening tool for ND in LCH, although optimal timing remains to be determined.

  • Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAF V600E loads

    by Julian Thalhammer, Eric Jeziorski, Perrine Marec-Bérard, Mohamed Aziz Barkaoui, Anne Pagnier, Pierre-Simon Rohrlich, Aurore Chevallier, Liana Carausu, Nathalie Aladjidi, Charlotte Rigaud, et al.

    Hematological involvement (HI) is one of the life-threatening risk organs (ROs) in Langerhans cell histiocytosis (LCH). Lahey criteria have defined HI since 1975 as hemoglobin 20 × 109/L, respectively) and severe HI (SHI; ≤7 g/dL and/or ≤20 × 109/L). Each entity has different organ involvements, laboratory parameters, mutational status, blood BRAFV600E loads, drug sensitivities, and outcomes (MHI and SHI 10-year survival rates, 98% and 73%, respectively). Since 1998, mortality first declined with combination cladribine-cytarabine therapy and then with MAPK inhibitors since 2014. Forty-one patients (12%) developed neurodegenerative complications that have emerged as a risk for long-term survivors. These results suggest limiting the HI-RO definition to SHI, because it encompasses almost all medical complications of LCH. Future clinical trials might demonstrate that targeted therapy approaches would be better adapted for these patients, whereas MHI can be managed with classic therapies.


  • A circulating subset of BRAFV600E‐positive cells in infants with high‐risk Langerhans cell histiocytosis treated with BRAF inhibitors

    by Rita Poch, Solenne Le Louet, Zofia Hélias‐Rodzewicz, Nawa Hachem, Geneviève Plat, Mohamed‐Aziz Barkaoui, Hélène Lapillonne, François Delhommeau, Jean‐François Emile, Jean Donadieu, et al.

    Summary: BRAF inhibitors are an effective treatment for BRAFV600E‐mutated, risk‐organ‐positive Langerhans cell histiocytosis (RO+ LCH). However, cell‐free BRAFV600E DNA often persists during therapy and recurrence frequently occurs after therapy discontinuation. To identify a pathological reservoir of BRAFV600E‐mutated cells, we studied peripheral blood cells obtained from six infants with RO+ multisystem (MS) LCH that received targeted therapy. After cell sorting, the BRAFV600E mutation was detected in monocytes (n = 5), B lymphocytes (n = 3), T lymphocytes (n = 2), and myeloid and plasmacytoid dendritic cells (n = 2 each). This biomarker may offer an interesting tool for monitoring the effectiveness of new therapeutic approaches for weaning children with RO+ LCH from targeted therapy.


  • Open Access

    Childhood Langerhans cell histiocytosis with severe lung involvement: a nationwide cohort study

    by Solenne Le Louet, Mohamed-Aziz Barkaoui, Jean Miron, Claire Galambrun, Nathalie Aladjidi, Pascal Chastagner, Kamila Kebaili, Corinne Armari-Alla, Anne Lambilliotte, Julien Lejeune, et al.

    Background: Lung involvement in childhood Langerhans cell histiocytosis (LCH) is infrequent and rarely life threatening, but occasionally, severe presentations are observed.Methods: Among 1482 children (< 15 years) registered in the French LCH registry (1994–2018), 111 (7.4%) had lung involvement. This retrospective study included data for 17 (1.1%) patients that required one or more intensive care unit (ICU) admissions for respiratory failure.Results: The median age was 1.3 years at the first ICU hospitalization. Of the 17 patients, 14 presented with lung involvement at the LCH diagnosis, and 7 patients (41%) had concomitant involvement of risk-organ (hematologic, spleen, or liver). Thirty-five ICU hospitalizations were analysed. Among these, 22 (63%) were secondary to a pneumothorax, 5 (14%) were associated with important cystic lesions without pneumothorax, and 8 (23%) included a diffuse micronodular lung infiltration in the context of multisystem disease.First-line vinblastine–corticosteroid combination therapy was administered to 16 patients; 12 patients required a second-line therapy (cladribine:n = 7; etoposide-aracytine:n = 3; targeted therapyn = 2). A total of 6 children (35%) died (repeated pneumothorax:n = 3; diffuse micronodular lung infiltration in the context of multisystem disease:n = 2; following lung transplantation:n = 1). For survivors, the median follow-up after ICU was 11.2 years. Among these, 9 patients remain asymptomatic despite abnormal chest imaging.Conclusions: Severe lung involvement is unusual in childhood LCH, but it is associated with high mortality. Treatment guidelines should be improved for this group of patients: viral infection prophylaxis and early administration of a new LCH therapy, such as targeted therapy.